Literature DB >> 26424647

EBV Persistence--Introducing the Virus.

David A Thorley-Lawson1.   

Abstract

Persistent infection by EBV is explained by the germinal center model (GCM) which provides a satisfying and currently the only explanation for EBVs disparate biology. Since the GCM touches on every aspect of the virus, this chapter will serve as an introduction to the subsequent chapters. EBV is B lymphotropic, and its biology closely follows that of normal mature B lymphocytes. The virus persists quiescently in resting memory B cells for the lifetime of the host in a non-pathogenic state that is also invisible to the immune response. To access this compartment, the virus infects naïve B cells in the lymphoepithelium of the tonsils and activates these cells using the growth transcription program. These cells migrate to the GC where they switch to a more limited transcription program, the default program, which helps rescue them into the memory compartment where the virus persists. For egress, the infected memory cells return to the lymphoepithelium where they occasionally differentiate into plasma cells activating viral replication. The released virus can either infect more naïve B cells or be amplified in the epithelium for shedding. This cycle of infection and the quiescent state in memory B cells allow for lifetime persistence at a very low level that is remarkably stable over time. Mathematically, this is a stable fixed point where the mechanisms regulating persistence drive the state back to equilibrium when perturbed. This is the GCM of EBV persistence. Other possible sites and mechanisms of persistence will also be discussed.

Entities:  

Mesh:

Year:  2015        PMID: 26424647      PMCID: PMC5125397          DOI: 10.1007/978-3-319-22822-8_8

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  248 in total

1.  Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells.

Authors:  Donna Hochberg; Tatyana Souza; Michelle Catalina; John L Sullivan; Katherine Luzuriaga; David A Thorley-Lawson
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 2.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas.

Authors:  David A Thorley-Lawson; Andrew Gross
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

3.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals.

Authors:  R G Caldwell; J B Wilson; S J Anderson; R Longnecker
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

4.  A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals.

Authors:  Q Y Yao; A B Rickinson; M A Epstein
Journal:  Int J Cancer       Date:  1985-01-15       Impact factor: 7.396

Review 5.  Germinal centers.

Authors:  I C MacLennan
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

6.  Relationship between the Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination.

Authors:  M Andersson-Anvret; N Forsby; G Klein; W Henle
Journal:  Int J Cancer       Date:  1977-10-15       Impact factor: 7.396

7.  Epstein-Barr virus latent membrane protein 1 genetic variability in peripheral blood B cells and oropharyngeal fluids.

Authors:  Nicholas Renzette; Mohan Somasundaran; Frank Brewster; James Coderre; Eric R Weiss; Margaret McManus; Thomas Greenough; Barbara Tabak; Manuel Garber; Timothy F Kowalik; Katherine Luzuriaga
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

Review 8.  Discovery of activation-induced cytidine deaminase, the engraver of antibody memory.

Authors:  Masamichi Muramatsu; Hitoshi Nagaoka; Reiko Shinkura; Nasim A Begum; Tasuku Honjo
Journal:  Adv Immunol       Date:  2007       Impact factor: 3.543

9.  Epstein-Barr virus maintains lymphomas via its miRNAs.

Authors:  D T Vereide; E Seto; Y-F Chiu; M Hayes; T Tagawa; A Grundhoff; W Hammerschmidt; B Sugden
Journal:  Oncogene       Date:  2013-03-18       Impact factor: 9.867

Review 10.  How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma?

Authors:  Martin J Allday
Journal:  Semin Cancer Biol       Date:  2009-07-25       Impact factor: 15.707

View more
  114 in total

1.  Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.

Authors:  Allan Hildesheim; Denise L Doolan; Anna E Coghill; Ruth M Pfeiffer; Carla Proietti; Wan-Lun Hsu; Yin-Chu Chien; Lea Lekieffre; Lutz Krause; Andy Teng; Jocelyn Pablo; Kelly J Yu; Pei-Jen Lou; Cheng-Ping Wang; Zhiwei Liu; Chien-Jen Chen; Jaap Middeldorp; Jason Mulvenna; Jeff Bethony
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

2.  Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virus-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but Are Not Essential.

Authors:  Shi-Dong Ma; Ming-Han Tsai; James C Romero-Masters; Erik A Ranheim; Shane M Huebner; Jillian A Bristol; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

3.  Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival.

Authors:  Kai-Min Lin; Sue-Jane Lin; Juin-Han Lin; Pei-Yi Lin; Pu-Lin Teng; Hsueh-Erh Wu; Te-Huei Yeh; Ying-Piao Wang; Mei-Ru Chen; Ching-Hwa Tsai
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

Review 4.  Known unknowns: how might the persistent herpesvirome shape immunity and aging?

Authors:  Janko Nikolich-Zugich; Felicia Goodrum; Kenneth Knox; Megan J Smithey
Journal:  Curr Opin Immunol       Date:  2017-08-04       Impact factor: 7.486

Review 5.  Hitchhiking of Viral Genomes on Cellular Chromosomes.

Authors:  Tami L Coursey; Alison A McBride
Journal:  Annu Rev Virol       Date:  2019-07-05       Impact factor: 10.431

6.  TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.

Authors:  Mahiuddin Ahmed; Andres Lopez-Albaitero; Dmitry Pankov; Brian H Santich; Hong Liu; Su Yan; Jingyi Xiang; Pei Wang; Aisha N Hasan; Annamalai Selvakumar; Richard J O'Reilly; Cheng Liu; Nai-Kong V Cheung
Journal:  JCI Insight       Date:  2018-02-22

7.  MYC Controls the Epstein-Barr Virus Lytic Switch.

Authors:  Rui Guo; Chang Jiang; Yuchen Zhang; Apurva Govande; Stephen J Trudeau; Fang Chen; Christopher J Fry; Rishi Puri; Emma Wolinsky; Molly Schineller; Thomas C Frost; Makda Gebre; Bo Zhao; Lisa Giulino-Roth; John G Doench; Mingxiang Teng; Benjamin E Gewurz
Journal:  Mol Cell       Date:  2020-04-20       Impact factor: 17.970

Review 8.  Epigenetics and Genetics of Viral Latency.

Authors:  Paul M Lieberman
Journal:  Cell Host Microbe       Date:  2016-05-11       Impact factor: 21.023

Review 9.  Molecular mechanisms of viral oncogenesis in humans.

Authors:  Nathan A Krump; Jianxin You
Journal:  Nat Rev Microbiol       Date:  2018-11       Impact factor: 60.633

Review 10.  Idiopathic nephrotic syndrome: the EBV hypothesis.

Authors:  Claire Dossier; Agnès Jamin; Georges Deschênes
Journal:  Pediatr Res       Date:  2016-09-28       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.